U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314723) titled '9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer' on Dec. 18, 2025.
Brief Summary: This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
Study Start Date: Aug. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Intervention:
DRUG: 9MW2821
9MW2821, 1.25mg/kg, intravenous (IV) infusion
DRUG: Toripalimab Injection
Toripalimab, 240mg, intravenous (IV) infusion
Recruitment Status: RECRUITING
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
...